In Segment A, members will receive different doses and schedules of oral ABBV-744 tablet to establish Harmless dosing regimen. Added contributors are going to be enrolled in the determined monotherapy dosign routine. In Phase B, participants will obtain oral ruxolitinib and ABBV-744 will likely be specified as "add-on" therapy. In https://jinnahn877boz1.bloggactif.com/profile